Datapoint: Jakafi Approved for Chronic GVHD

The FDA last week approved Incyte Corp.’s JAK inhibitor Jakafi for the treatment of chronic graft-versus-host disease (GVHD) in patients that have not responded to one or two other lines of systemic therapy. Jakafi, which is already approved for the acute form of the disease, currently holds covered or better status for 70% of all insured lives.

SOURCE: MMIT Analytics, as of 9/23/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 24

Datapoint: Georgia Doubles Down on Partial Medicaid Expansion Waiver

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today